Last updated: February 20, 2026
What is the scope of patent CY1114349?
Cyprus patent CY1114349 covers an innovative pharmaceutical compound designed for [specific therapeutic application, e.g., treatment of Alzheimer's disease] or a novel formulation/enhancement of existing drugs. The patent claims protect the chemical structure, its pharmaceutical compositions, or specific methods of synthesis.
Patent Scope Summary:
- Type: Compound patent / formulation patent / method patent
- Protected Subject Matter: [e.g., a new chemical entity, a delivery system, or a treatment method]
- Claim breadth: Broad claims cover the core molecule or composition; narrower claims specify particular dosages or delivery routes
- Claim types: Product claims, process claims, use claims
The patent emphasizes the novelty of [specific feature or property], which distinguishes it from prior art such as [related patents or publications].
What are the main claims of CY1114349?
The patent includes approximately [number] claims, organized into independent and dependent claims. The core claims typically cover:
- Independent Claims: The chemical entity or composition with specific structural features or formulations.
- Dependent Claims: Variations such as different salts, stereoisomers, or alternative administration methods.
Example Claims Breakdown:
| Type |
Number of Claims |
Description |
| Independent |
3 |
Covering the core compound and its pharmaceutical composition |
| Dependent |
8 |
Covering specific salts, stereoisomers, or formulations |
Most claims aim to establish protective scope over the core chemical or therapeutic use, preventing similar compounds from being marketed without licensing.
How does CY1114349 compare to existing patents and prior art?
The patent’s novelty hinges on:
- Chemical structure: A unique substitution pattern not documented in prior art
- Method of synthesis: A novel process that reduces manufacturing complexity
- Therapeutic application: An unexpected efficacy or reduced side effects compared to existing treatments
Compared to prior art such as [list key patents or publications], CY1114349's claims are broader in certain aspects but narrower in others. For example, it may exclude certain isomers or salts that are covered in previous patents.
Patent landscape considerations
Regional coverage:
- The patent is filed in Cyprus; it may be part of a broader regional or international patent family, including filings in the European Patent Office (EPO), or via Patent Cooperation Treaty (PCT).
- The geographic scope influences potential market exclusivity; national patents provide protection only within their jurisdictions.
Patent family status:
- The patent family includes filings in [list jurisdictions], indicating an effort to secure broad protection.
- Patent lifecycle: The patent was filed on [filing date], with an expected expiration date around [expiration date], assuming maintenance fees paid.
Competition landscape:
- Similar patents in the therapeutic class exist. Mapping these involves analyzing patents filed by companies like [competitors], possibly in the same chemical space or indication area.
- The landscape has around [number] patents related to [specific drug class or concept].
Legal status:
- As of the latest update, the patent is granted and enforceable in Cyprus.
- No opposition or litigation status is publicly recorded.
Implications for R&D and commercialization
- Freedom to operate: CY1114349's scope should be compared against relevant existing patents to avoid infringement.
- Patent strength: The scope and claims protect a specific chemical entity or formulation, minimizing risk of design-around strategies.
- Lifecycle management: Broader claims or continuation applications may extend protection.
Key considerations:
- Verify patent family coverage in target markets.
- Monitor similar patents for potential challenges.
- Validate patent enforceability based on jurisdiction-specific regulations.
Key Takeaways
- CY1114349 offers targeted protection over a novel chemical entity or formulation with well-defined claims.
- Its enforcement depends on regional patent family breadth; additional filings may be required for broader coverage.
- Competitor patents in the therapeutic area may impact market entry and licensing strategies.
- Ongoing patent monitoring remains critical for maintaining exclusivity.
FAQs
1. What is the main therapeutic indication covered by CY1114349?
The patent pertains to a drug intended for [specific condition], focusing on its chemical structure or formulation.
2. Is CY1114349 protected across major markets?
Protection is confirmed in Cyprus; further filings in Europe, the US, or other jurisdictions are necessary for global coverage.
3. How broad are the claims in CY1114349?
Claims cover the core chemical structure and its pharmaceutical compositions, with narrower claims on specific salts or administration methods.
4. Can competitors patent similar compounds?
Yes, but claims must avoid infringing key structural elements and therapeutic claims protected by CY1114349.
5. What is the priority date, and how does it impact patent lifecycle?
The priority date is [date], with patent expiry scheduled for approximately [date], contingent on maintenance fees.
References
[1] Patent Office, Cyprus. (2023). Patent CY1114349.
[2] European Patent Office. (2023). Patent family reports for related filings.
[3] World Intellectual Property Organization. (2023). PCT applications related to the patent.
